Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KIT V559A||melanoma||predicted - sensitive||KIT Inhibitor||Imatinib||Case Reports/Case Series||Actionable||In a clinical case study, Gleevec (imatinib) treatment in a patient with metastatic melanoma resulted in regression of the lung metastasis, which harbored KIT V559A; however, neither the primary tumor or lymph node metastasis responded, which had wild-type KIT (PMID: 19812602).||19812602|
|KIT V559A||melanoma||sensitive||KIT Inhibitor||Nilotinib||Case Reports/Case Series||Actionable||In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), including a melanoma patient harboring KIT V559A demonstrating a partial response and progression-free survival of 19.4 months and overall survival of 32.9 months (PMID: 28327988).||28327988|
|KIT V559A||gastrointestinal stromal tumor||predicted - resistant||KIT Inhibitor||Imatinib||Case Reports/Case Series||Actionable||In a clinical study, KIT V559A was identified as a secondary mutation in a patient with gastrointestinal stromal tumor who developed resistance to Gleevec (imatinib) (PMID: 18488160).||18488160|
|KIT V559A||Advanced Solid Tumor||sensitive||KIT Inhibitor||Axitinib||Preclinical - Cell culture||Actionable||In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT V559A in culture (PMID: 31205508).||31205508|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|